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Objective.To perform a genome-wideDNAmethyl-
ation study to identify DNA methylation changes in
osteoarthritic (OA) cartilage tissue.
Methods. The contribution of differentially meth-
ylated genes to OA pathogenesis was assessed by bio-
informatic analysis, gene expression analysis, and his-
topathologic severity correlation. Genome-wide DNA
methylation profiling of >485,000 methylation sites was
performed on eroded and intact cartilage from within
the same joint of 24 patients undergoing hip arthro-
plasty for OA. Genes with differentially methylated
CpG sites were analyzed to identify overrepresented
gene ontologies, pathways, and upstream regulators.
The messenger RNA expression of a subset of differ-
entially methylated genes was analyzed by reverse
transcription–polymerase chain reaction. Histopathol-
ogy was graded by modified Mankin score and corre-
lated with DNA methylation.
Results. We identified 550 differentially methyl-
ated sites in OA. Most (69%) were hypomethylated and
enriched among gene enhancers. We found differential
methylation in genes with prior links to OA, including
RUNX1, RUNX2, DLX5, FURIN, HTRA1, FGFR2,
NFATC1, SNCAIP, and COL11A2. Among these, RUNX1,
HTRA1, FGFR2, and COL11A2 were also differentially
expressed. Furthermore, we found differential methyl-
ation in approximately one-third of known OA sus-
ceptibility genes. Among differentially methylated
genes, upstream regulator analysis showed enrichment
of TGFB1 (P  4.40  105) and several microRNAs
including miR-128 (P  4.48  1013), miR-27a (P 
4.15  1012), and miR-9 (P  9.20  1010). Finally,
we identified strong correlations between 20 CpG sites
and the histologic Mankin score in OA.
Conclusion. Our data implicate epigenetic dys-
regulation of a host of genes and pathways in OA,
including a number of OA susceptibility genes. Further-
more, we identified correlations between CpG methyl-
ation and histologic severity in OA.
Osteoarthritis (OA) is a chronic, debilitating
musculoskeletal disease characterized by progressive
loss of function of both load-bearing and non–load-
bearing joints, leading to significant pain and functional
limitation. Although a hallmark of OA is loss of hyaline
cartilage leading to joint space narrowing, other articular
tissues and processes have been implicated, including
synovial inflammation and subchondral bone remodel-
ing. An unrecognized epidemic, OA is the leading cause
of chronic disability in the US, affecting 40% of US
adults age 70 years (1). Indeed, the risk of disability
resulting from knee or hip OA is equivalent to that
resulting from cardiovascular disease (2). Recent esti-
mates place the annual cost of OA at $128 billion in the
US, representing nearly 1% of gross domestic product
(3). Alarmingly, the prevalence of severe OA requiring
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joint replacement is increasing at a rate that exceeds
expected increases due to obesity and aging (4).
Unlike many other rheumatic diseases, relatively
little is known about the pathophysiology of OA. Con-
sequently, treatment options remain diminutive, consist-
ing principally of analgesic agents and viscosupplemen-
tation. Remarkably, although the incidence of OA is
400-fold higher than that of rheumatoid arthritis (RA)
(5), there have been no disease-modifying agents ap-
proved for the treatment of OA. More must be done to
understand the mechanisms involved in the develop-
ment and progression of OA to move the field toward
novel therapeutic strategies.
The pathogenesis of OA involves the interplay of
3 major factors: genetic predisposition, aging, and the
environment (6). Genome-wide association studies
have identified surprisingly few candidate genetic suscep-
tibility loci, the majority of which are within either
structural genes or cellular signaling pathways (7–9).
Several studies have recently implicated epigenetic dys-
regulation as a contributor to OA pathology. Epigenet-
ics, defined as heritable changes in gene expression that
occur in the absence of mutations of underlying genomic
DNA, is a common mechanism whereby organisms alter
gene expression in response to both external and inter-
nal environmental cues. Epigenetic regulation occurs by
a few common mechanisms, including genomic DNA
methylation, alterations of histone side chains resulting
in chromatin conformational change, and noncoding
RNA feedback. Epigenetic dysregulation leading to
inappropriate gene expression or silencing has been
shown to play an important role in several rheumatic
diseases, such as systemic lupus erythematosus (10–12)
and RA (13–15).
The most widely studied epigenetic control mech-
anism is DNA methylation. The addition of methyl
groups to the 5 position of cytosine in fully differenti-
ated tissues most commonly occurs in CpG dinucleo-
tides, mediated by a variety of DNA methyltransferases.
Methylation of certain regulatory regions is of particular
transcriptional relevance, most commonly within the
5-untranslated region (5-UTR) or 5-promoter region
upstream of a target gene or located near or within
CpG-enriched regions known as CpG islands. Methyl-
ated cytosines within these areas tend to be transcrip-
tionally repressive, whereas unmethylated cytosines are
permissive for gene expression. To date, few studies
have been undertaken to examine the role of epigenetics
in OA, but they have proven quite fruitful. Candidate
gene methylation analyses in OA cartilage have identi-
fied significant alterations in DNA methylation signa-
tures of the matrix metalloproteinases (MMPs) MMP3,
MMP6, MMP9, MMP13 (16), and ADAMTS4 (17), and,
curiously, the obesity- and inflammation-linked leptin
gene (18). A recent report described a genome-wide
DNA methylation analysis that examined the status of
27,000 CpG sites in OA knee cartilage compared to
normal control cartilage and identified a number of
differentially methylated CpG sites as well as a cluster of
cases that appeared enriched in inflammatory genes (19).
Our present work sought to expand this knowl-
edge of OA epigenetics in order to address 2 major
questions unanswered by previous studies. The first was
whether regional differences in methylation exist be-
tween eroded and intact cartilage within the same joint,
which may be linked to disease progression. We hypoth-
esized that many genes and pathways linked to OA
would have significant changes in their epigenetic state
as the disease progresses. Our second question was
whether CpG methylation varies linearly with OA dis-
ease activity; we hypothesized that several differentially
methylated CpG sites would be highly correlated with
histologic score. To address these questions, we per-
formed the largest survey, pathway, and ontological
analysis to date of the methylation status of 485,000
CpG sites throughout the entire genome of paired
samples of eroded and intact cartilage obtained from hip
joints of 24 OA patients. Additionally, we performed
histopathologicmodifiedMankinscoring(20)andmethyl-
ation correlation analyses on 12 samples, as well as
limited gene expression profiling of selected differen-
tially methylated genes in a subset of 12 samples.
MATERIALS AND METHODS
Samples and nucleic acid isolation. Twenty-four fem-
oral heads were obtained from patients undergoing hip arthro-
plasty for end-stage primary OA at the McBride Orthopedic
Hospital in Oklahoma City. Demographic information about
these patients is presented in Supplementary Table 1, avail-
able on the Arthritis & Rheumatology web site at http://online
library.wiley.com/doi/10.1002/art.38762/abstract. The Institu-
tional Review Boards in all involved institutions approved this
study. Full-thickness cartilage samples representing grossly
eroded and grossly intact cartilage were obtained from areas
of each femoral head, divided into portions for DNA and RNA
extraction, and flash-frozen in liquid nitrogen. Additional
portions of tissue were collected from 6 femoral heads and
placed in 4% paraformaldehyde (Sigma-Aldrich) for subse-
quent histologic analysis. Samples were then ground using
either a mortar and pestle or a cryogenic grinder mill (Spex
CertiPrep). DNA was isolated from each sample using a
DNeasy kit (Qiagen), and 500 ng was subsequently treated
with sodium bisulfite using an EZ-DNA Methylation-
Lightning kit (Zymo Research).
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DNA methylation studies. Genome-wide DNA methyl-
ation was assessed using the HumanMethylation 450 Bead-
Chip microarray (Illumina), which analyzes the methylation
status of 485,000 methylation sites throughout the genome,
covering 99% of RefSeq genes at an average of 17 CpG sites
per gene across the 5-UTR, gene promoter regions, first exon,
gene body, and 3-UTR, and covering 96% of University of
California, Santa Cruz–defined CpG islands and their flanking
regions. Following bisulfite treatment, DNA from each sample
was loaded onto chips and processed by the Oklahoma Med-
ical Research Foundation Genotyping Core Facility. This
array includes a variety of both sample-independent and
sample-dependent controls, which were evaluated in each chip.
Histologic examination. Following fixation, samples
were embedded in paraffin and slides were cut for both
hematoxylin and eosin and Safranin O staining. Two patholo-
gists (MES, ACA) scored each case using the modified Mankin
scale, and a mean score was determined (see Supplementary
Table 2, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38762/abstract).
Statistical analysis. Chips were imaged and data were
extracted using the GenomeStudio methylation module, ver-
sion 2011.1 (Illumina). The percent methylated cytosines at
each CpG site () was calculated as the ratio of methylated
probe signal to total locus signal intensity and defined within a
range of 0 to 1 by GenomeStudio; average  values were then
compared. Differentially methylated CpG sites were defined as
those having a differential methylation score 21, corre-
sponding to a P value of less than 0.01 after adjusting for
multiple testing using GenomeStudio’s built-in false discovery
rate function, which employs a Benjamini and Hochberg
procedure with   0.05. A second requirement was a mean
methylation difference ()  0.15 (15%) between the 2
groups. CpG sites with a known single-nucleotide polymor-
phism located within or 10 bp from the 3-end of the probe
were excluded. The locations of particular CpG sites within
regulatory regions were defined by GenomeStudio, including
CpG islands as well as North (5) and South (3) Shores
(N-Shores and S-Shores) and North (5) and South (3)
Shelves (N-Shelves and S-Shelves), which represent 2 kb
surrounding CpG islands and shores, respectively. Location
statistics were calculated using the Yates’ correction of a
chi-square distribution P value of a 2  2 contingency table.
Gene ontology analyses. Functional properties, net-
works, pathways, and upstream regulators enriched in differ-
entially methylated genes were assessed using the Ingenuity
Pathways Analysis (IPA) system (Ingenuity Systems) using the
Ingenuity Knowledge Base reference set. Direct and indirect
relationships were calculated, and experimentally observed
relationships were included; P values less than or equal to 0.05
were considered significant. In addition to the standard up-
stream regulator analysis, microRNAs (miRNAs) overrepre-
sented among differentially methylated genes were identified
by IPA using experimentally demonstrated and predicted
miRNA–messenger RNA (mRNA) interactions or binding
sites from TarBase, miRecords, and TargetScan databases, as
well as peer-reviewed miRNA research articles as curated by
Ingenuity Systems staff.
Histologic correlation. In the 12 samples with histo-
pathologic scores, CpG methylation at each site was compared
to the modified Mankin score. The coefficient of determina-
tion (R2) was calculated using a linear regression model.
Correlations were deemed significant if R2 was 0.85 and the
range of methylation values across samples for the CpG was at
least 15% (samples  0.15).
Reverse transcription–polymerase chain reaction (RT-
PCR). The expression profiles of several of the most differen-
tially hypomethylated and hypermethylated genes identified in
our assay were evaluated by real-time RT-PCR. RNA was
isolated using an Ambion RNAqueous kit (Life Technologies)
in accordance with the manufacturer’s instructions. Real-time
RT-PCR was performed with a RotorGene 3000 (Qiagen)
using an iScript one-step RT-PCR kit (Bio-Rad) with the
following cycling conditions: 30 minutes at 50°C, 15 minutes at
95°C, 70 cycles of 15 seconds at 94°C and 20 seconds at 56°C,
and 30 seconds at 72°C. Primer sequences are listed in
Supplementary Table 3, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38762/abstract. Relative mRNA concentrations were calcu-
lated by RotorGene6 software, using the Ct method with
GAPDH as a housekeeping gene. GAPDH Ct values were
similar among eroded and intact cartilage samples.
Array confirmation. DNA methylation values of se-
lected hypomethylated, intermediate-methylated, and hyper-
methylated CpGs within HOXA3, HOXA5, and HOXA9 were
determined by traditional bisulfite Sanger sequencing and
subsequent analysis using the ESME software package (Epi-
genomics) (21), a method we have used extensively in the past
(10). We found a high level of correlation between methyla-
tion values reported by the Illumina array and those found by
this traditional sequencing method (R2  0.84; n  193) (see
Supplementary Figure 1, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.38762/abstract).
Differential methylation confirmation. Finally, to
confirm differential methylation of 3 CpG sites among the
most highly differentially hypomethylated genes identified by
the Illumina array (cg19348484: FURIN; cg04915566 and
cg01519261: RUNX1), custom, commercial pyrosequencing
analysis was performed (EpigenDx) on a subset of 12 eroded
and 12 intact cartilage samples.
RESULTS
Significant differential CpG methylation between
eroded and intact OA cartilage. We identified a total of
550 differentially methylated CpG sites in grossly eroded
cartilage samples compared with intact samples. Of
these, 378 (69%) were hypomethylated and 172 (31%)
were hypermethylated (Table 1 and Figure 1), corre-
sponding to 390 distinct, known genes and nearby
genomic regions. Differentially methylated sites were
concentrated in enhancers, 50% observed among hy-
pomethylated sites (P  0.0001) and 37% observed
among hypermethylated CpGs (P 0.002), as compared
to 21% expected for both for the assay. Enhancers are
segments of regulatory genomic sequence that may exert
effects at remote locations to control both spatial and
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temporal gene expression. Additional enrichment was
noted in the N-Shore regions of CpG islands among
hypomethylated CpGs (9% observed compared to 5%
expected; P  0.03) and within gene bodies among
hypermethylated CpGs (68% observed compared to
36% expected; P 0.0001) (see Supplementary Table 4,
available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38762/
abstract).
Differential methylation among several genes
implicated in OA pathology. The most hypomethylated
CpG site in our analysis was in the 5-UTR of FURIN,
encoding a proprotein convertase. Previous studies have
found FURIN to be significantly overexpressed in OA
cartilage (22), which is consistent with our methylation
findings; however, we did not find evidence of overex-
pression in our samples (mean SEM 2.4 0.8 relative
units for eroded cartilage versus 1.5  0.3 relative units
Table 1. Top CpG sites differentially hypomethylated and hypermethylated in eroded compared to intact cartilage*
CpG site methylation
status, Illumina CpG
ID no.
Associated
gene
symbol
Mean ,
eroded
Mean ,
intact 
Differential score,
FDR corrected
P, FDR
corrected
UCSC
location
group
UCSC
island
group
Located in
enhancer
Hypomethylated
cg19348484 FURIN 0.39 0.68 	0.30 	347.21 2.00  10	38 5-UTR N-Shore Yes
cg04915566 RUNX1 0.24 0.52 	0.27 	347.21 2.00  10	38 5-UTR – –
cg03278514 NA 0.26 0.53 	0.27 	347.21 2.00  10	38 – – Yes
cg25388800 NA 0.21 0.47 	0.26 	347.21 2.00  10	38 – – Yes
cg18873386 DLX5 0.47 0.73 	0.26 	347.21 2.00  10	38 Gene body N-Shore –
cg01519261 RUNX1 0.32 0.57 	0.26 	347.21 2.00  10	38 5-UTR – –
cg25928986 NA 0.37 0.62 	0.25 	347.21 2.00  10	38 – S-Shore –
cg16017420 NA 0.41 0.66 	0.25 	347.21 2.00  10	38 – S-Shelf –
cg13784312 RAPGEF1 0.37 0.62 	0.25 	347.21 2.00  10	38 Gene body – –
cg12534147 NA 0.27 0.52 	0.24 	347.21 2.00  10	38 – – Yes
cg12686441 NA 0.29 0.53 	0.23 	347.21 2.00  10	38 – – –
cg08369079 PRDM1 0.43 0.66 	0.23 	347.21 2.00  10	38 Gene body – –
cg11756029 TRAFD1 0.30 0.53 	0.23 	347.21 2.00  10	38 Gene body – –
cg10193711 NA 0.31 0.54 	0.23 	347.21 2.00  10	38 – – –
cg27016494 DLX5 0.53 0.76 	0.23 	347.21 2.00  10	38 Gene body N-Shore –
cg16152753 NA 0.36 0.58 	0.22 	347.21 2.00  10	38 – S-Shelf –
cg09966895 ODZ4 0.21 0.44 	0.22 	347.21 2.00  10	38 Gene body – Yes
cg15840891 NA 0.23 0.45 	0.22 	347.21 2.00  10	38 – – Yes
cg05101437 CDK6 0.33 0.55 	0.22 	347.21 2.00  10	38 Gene body – Yes
cg01510278 NA 0.28 0.49 	0.22 	347.21 2.00  10	38 – – Yes
cg05973398 RUNX1 0.26 0.47 	0.22 	347.21 2.00  10	38 Gene body – Yes
Hypermethylated
cg04152616 NA 0.58 0.38 0.19 349.79 1.05 10	38 –
cg27317046 LTBP2 0.48 0.28 0.19 349.79 1.05 10	38 Gene body – Yes
cg12226006 FGFR2 0.65 0.46 0.19 349.79 1.05 10	38 Gene body – Yes
cg22251148 NA 0.49 0.30 0.19 349.79 1.05 10	38 – N-Shore –
cg10707788 GMDS 0.58 0.38 0.20 349.79 1.05 10	38 Gene body – –
cg00281273 LPCAT1 0.45 0.26 0.20 349.79 1.05 10	38 Gene body – –
cg14856220 FGFR2 0.64 0.44 0.20 349.79 1.05 10	38 TSS 200 N-Shelf –
cg12528056 GPR44 0.51 0.31 0.20 349.79 1.05 10	38 3-UTR Island –
cg24812143 KIAA1274 0.52 0.32 0.20 349.79 1.05 10	38 Gene body – Yes
cg14196395 DYSF 0.60 0.40 0.20 349.79 1.05 10	38 Gene body – –
cg05522011 PRDM8 0.65 0.45 0.20 349.79 1.05 10	38 Gene body N-Shore –
cg23938483 C14orf43 0.67 0.47 0.20 349.79 1.05 10	38 3-UTR Island –
cg10628201 UBE2L3 0.49 0.28 0.20 349.79 1.05 10	38 Gene body – Yes
cg20277356 FGFR2 0.72 0.51 0.22 349.79 1.05 10	38 TSS 200 N-Shelf –
cg00730832 FGFR2 0.65 0.43 0.22 349.79 1.05 10	38 TSS 1,500 N-Shelf –
cg10314760 FGFR2 0.67 0.45 0.22 349.79 1.05 10	38 TSS 200 N-Shelf –
cg14834653 FGFR2 0.69 0.46 0.23 349.79 1.05 10	38 TSS 200 N-Shelf –
cg17239876 KIAA1274 0.51 0.28 0.23 349.79 1.05 10	38 Gene body – Yes
cg13175830 FGFR2 0.59 0.36 0.23 349.79 1.05 10	38 TSS 200 N-Shelf –
cg24974704 ZC3H3 0.53 0.28 0.24 349.79 1.05 10	38 Gene body – –
cg21036194 SNCAIP 0.86 0.61 0.26 349.79 1.05 10	38 Gene body – –
*   absolute difference in methylation value between sample groups (eroded 	 intact); FDR  false discovery rate; UCSC  University of
California, Santa Cruz; 5-UTR  5-untranslated region; N  North; NA  not applicable; S  South; TSS 200  within 200 bp of transcription
start site.
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for intact cartilage; P  0.29) (Figure 2D). Significant
hypomethylation of this CpG site was independently
confirmed by pyrosequencing analysis (cg19348484:  
0.35, P  1.7  10	4) (see Supplementary Figure 2, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38762/abstract).
The second and sixth most hypomethylated CpG
sites were within the 5-UTR of RUNX1, previously
identified as differentially methylated in OA. We iden-
tified 6 additional hypomethylated sites associated with
this gene. Counterintuitively, we found an 50% reduc-
tion of expression in eroded cartilage (1.2  0.2 relative
units versus 2.6  0.3 relative units; P  0.002) (Figure
2G). Significant hypomethylation of 2 RUNX1 CpG
Figure 2. Relative mRNA expression of selected hypomethylated and
hypermethylated genes associated with differentially methylated CpG
sites, assessed by reverse transcription–polymerase chain reaction.
Values are mean SEM relative units for eroded cartilage (solid bars)
versus relative units for intact cartilage (shaded bars), respectively.
A, Hypermethylated COL11A2: 3.7  1 versus 15  0.8 (P  0.0002).
B, Hypomethylated DLX5: 4.9  1 versus 9.9  1 (P  0.07). C, Hy-
permethylated FGFR2: 0.43  0.2 versus 1.8  0.2 (P  0.01). D,
Hypomethylated FURIN: 2.4  0.8 versus 1.5  0.3 (P  0.29).
E, Hypomethylated HTRA1: 7.4  1.4 versus 1.4  0.4 (P  0.002).
F, Hypermethylated NFATC1: 2.13  0.4 versus 1.87  0.4 (P 
0.76). G, Hypomethylated RUNX1: 1.2  0.2 versus 2.6  0.3
(P  0.002). H, Hypomethylated RUNX2: 0.75  0.1 versus 0.82 
0.3 (P  0.9). I, Hypermethylated SNCAIP: 6.8  4 versus 3.5  2
(P  0.6).
Figure 1. Heatmap of 550 differentially methylated CpG sites among
eroded and intact cartilage samples from femoral heads of 24 patients
with osteoarthritis. Rows represent differentially methylated CpG
sites. Columns represent samples. Red indicates hypermethylated.
Green indicates hypomethylated.
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sites was independently confirmed by pyrosequencing
analysis (cg04915566:   0.28, P  5.1  10	5;
cg01519261:   0.22, P  7.66  10	5) (see Supple-
mentary Figure 2, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38762/abstract). Our analysis also identified
2 hypomethylated CpG sites associated with RUNX2, 1
within a CpG island N-Shelf and 1 in the 5-UTR of the
gene. RUNX2 is highly associated with OA and is
overexpressed in OA chondrocytes; however, we did not
find a significant difference in expression of RUNX2
among our samples (0.75 0.1 relative units for eroded
cartilage versus 0.82 0.3 relative units for intact carti-
lage; P  0.9) (Figure 2H).
We identified 8 significantly hypomethylated
CpG sites in both the body and within 1,500 bp of the
transcription start site (TSS) of DLX5, which plays an
important role in chondrogenesis and induces the ex-
pression of Runx2 (23). Our studies indicate that DLX5
is epigenetically poised for expression; however, we did
not find a significant difference in expression among
samples (4.9 1 relative units for eroded cartilage
versus 9.9 1 relative units for intact cartilage; P 
0.07) (Figure 2B). We found hypomethylation of 1 CpG
site within 1,500 bp of the TSS of HTRA1, a member of
the high-temperature requirement family of serine pro-
teases which is elevated in synovial fluid and cartilage of
OA patients, and we found overexpression of HTRA1
(7.4 1.4 relative units for eroded cartilage versus 1.4
0.4 relative units for intact cartilage; P  0.002) (Figure
2E), strongly suggesting epigenetic activation. Next, we
found 2 significantly hypermethylated CpGs within an
island and S-Shore associated with NFATC1, a member
of the nuclear factor of activated T cells family which
functions as a key suppressor of OA, but we did not find
evidence for differential expression in our samples
(2.13  0.4 relative units for eroded cartilage versus
1.87  0.4 relative units for intact cartilage; P  0.76)
(Figure 2F).
Among structural genes, we found hypermethyl-
ation of 2 CpG sites within the body of COL11A2,
which encodes the pro-2(XI) chain of type XI collagen
that maintains the diameter and cohesive strength of
cartilage matrices (24). Furthermore, we identified a
75% reduction in COL11A2 expression in eroded carti-
lage, which corroborates a functional consequence of
this hypermethylation (3.7  1 relative units for eroded
cartilage versus 15  0.8 relative units for intact carti-
lage; P  0.0002) (Figure 2A). FGFR2 is involved in
chondrocyte differentiation. We found 12 hypermethy-
lated CpGs within 200 bp of the TSS or within the
N-Shelf of CpG islands associated with FGFR2. Concor-
dantly, we found a 77% reduction in gene expression
(0.43  0.2 relative units for eroded cartilage versus
1.8  0.2 relative units for intact cartilage; P  0.01)
(Figure 2C).
Differential methylation among many OA sus-
ceptibility genes. We next turned our attention to the
methylation status of known OA susceptibility genes.
We reduced the absolute methylation difference ()
threshold requirement for differential methylation
from 15% to 10% and found 83 CpG sites among 24
of 64 recently reported susceptibility genes, including
ADAM12, ACAN, CALM1, CLIP, COL1A1, COL2A1,
COL9A2, COL11A2, DOT1L, ENPP1, ESR1, FRZB,
FTO, IGF2, IL10, IL1RN, ITGA6, LRP5, MMP3,
NCOR2, SERPINA3, SUPT3H, TGFB1, and TP63
(Table 2).
Gene ontology and network analysis show that
differentially methylated genes cluster among known
OA effectors. Next, we performed IPA to determine
networks, diseases, pathways, biologic functions, and
upstream regulators associated with differentially meth-
ylated genes. The most highly enriched network in-
cluded many genes known to be associated with OA, and
centered on SMAD3 (Figure 3A). A second network
involved several genes associated with OA, including
HTRA1, NFATC1, and DLX5 (Figure 3B). The top
overrepresented biologic functions were “development
of cardiovascular system” (P  3.45  10	8; n  44
genes) and “development of connective tissue” (P 
9.79  10	6; n  18 genes). Interestingly, 5 of the top 7
most highly overrepresented functional categories in-
volved angiogenesis or cardiovascular development. Im-
munologic functions were overrepresented as well, with
“cell movement of T lymphocytes” (P  5.39  10	6;
n 14 genes). The top canonical pathway identified was
“regulation of interleukin-2 expression in activated and
anergic T lymphocytes” (P  1.05  10	3) (see Supple-
mentary Table 5, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38762/abstract), highlighting both the
importance of inflammation in OA pathology and the
likely contribution of epigenetic control mechanisms to
OA inflammation.
Overrepresentation of transforming growth fac-
tor  (TGF) and both known and novel miRNA
associations among differentially methylated genes, as
demonstrated by upstream regulator analysis. Differen-
tially methylated genes were predicted to have a number
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of miRNA interactions (see Supplementary Table 6,
available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38762/
abstract); the top 3 included miR-128 (P 4.48 10	13;
n 50 genes), the MMP regulator miR-27a (P 4.15
10	12; n  43 genes), and the chondroblast survival
regulator miR-9 (P  9.20  10	10; n  48 genes). The
most enriched non-miRNAs included the protoonco-
gene ERG (P of overlap  9.49  10	6; n  11 genes),
the growth factor and OA effector TGFB1 (P of over-
lap  4.40  10	5; n  44 genes), the cytokine TNF (P
of overlap  1.27  10	4; n  41 genes), the inducer of
MMPs ELK1 (P of overlap 4.65 10	4; n 5 genes),
and the TGF-induced signaling molecule SMAD2 (P of
overlap  5.48  10	4; n  6 genes).
High correlation of several CpG sites with dis-
ease activity as measured by histopathologic score.
Finally, to study whether CpG methylation may be
correlated with OA progression, we performed histo-
logic modified Mankin scoring on a subset of our
samples (20,25). These had a variety of grades of OA; all
eroded portions had significantly higher scores than
intact portions within the same joint, confirming our
gross categorizations (see Supplementary Table 2, avail-
Table 2. CpG sites associated with known OA susceptibility genes*
OA susceptibility
gene
Illumina CpG
ID no. 
P,
FDR corrected
OA susceptibility
gene
Illumina CpG
ID no. 
P,
FDR corrected
ADAM12 cg02494582 0.13 1.1 10	35 DOT1L cg24430201 	0.11 2.7 10	15
cg27158677 	0.12 1.9  10	35 ENPP1 cg18796704 0.12 2.1 10	14
AGC1/ACAN cg03648457 0.10 4.8 10	11 ESR1 cg06611115 0.12 1.1 10	35
CALM1 cg18079499 	0.10 2.6  10	14 cg01321962 	0.10 2.4 10	10
CLIP cg16111364 0.10 3.4 10	13 cg07189962 	0.10 2.1 10	11
cg16434674 	0.15 6.2  10	24 FRZB cg02931467 0.10 5.4 10	10
COL1A1 cg14562086 	0.11 1.8  10	12 FTO cg09243909 0.17 1.1 10	35
cg18618815 	0.13 7.6  10	28 IGF2 cg02425416 	0.13 4.7 10	22
COL2A1 cg06118478 0.10 1.9 10	11 cg05777976 	0.11 1.9 10	12
COL9A2 cg04100190 0.11 2.0 10	13 cg19131227 	0.10 2.2 10	13
cg10210510 0.12 1.1 10	35 cg21532432 0.10 1.0 10	12
cg22799499 	0.10 1.4  10	12 IL10 cg15096505 0.14 1.1 10	35
COL11A2 cg04249605 0.15 1.1 10	35 IL1RN cg01467417 	0.10 1.0 10	10
cg08733307 0.14 1.1 10	35 ITGA6 cg22061832 	0.14 8.5 10	20
cg14683730 0.13 1.1 10	35 LRP5 cg08356705 	0.19 1.9 10	35
cg03260211 0.15 1.1 10	35 cg07985116 0.12 1.1 10	35
cg22161893 0.19 1.1 10	35 cg10771851 0.15 1.1 10	35
cg26998481 0.12 1.1 10	35 cg13894813 0.11 3.7 10	13
cg12472351 0.12 1.1 10	35 cg15302350 0.11 4.0 10	12
cg13703714 0.14 1.1 10	35 cg16409259 0.14 1.1 10	35
cg23704085 0.14 1.1 10	35 cg16414472 0.14 1.1 10	35
cg27512176 0.12 1.1 10	35 cg20278269 0.10 1.5 10	10
cg17560929 0.11 1.1 10	35 cg23949925 	0.11 1.2 10	12
cg20592734 0.12 2.1 10	14 cg13738327 0.19 1.1 10	35
cg12312338 0.11 4.1 10	14 MMP3 cg16466334 0.11 2.1 10	13
cg22501449 0.12 5.9 10	14 cg23438592 0.10 1.1 10	13
cg22320183 0.11 7.7 10	14 NCOR2 cg03406367 0.10 3.7 10	11
cg17636806 0.12 1.5 10	13 cg05395187 0.10 2.6 10	12
cg01412022 0.11 7.1 10	13 cg06242243 0.10 6.8 10	11
cg04137133 0.11 1.5 10	12 cg09831875 0.10 1.1 10	35
cg00669594 0.11 3.3 10	12 cg10082088 0.12 1.1 10	35
cg17591573 0.11 4.2 10	12 cg10849160 0.10 2.6 10	11
cg11411509 0.11 7.8 10	12 cg11197258 0.10 3.3 10	9
cg22361816 0.10 3.7 10	11 cg16706240 0.10 1.6 10	9
cg23231727 0.10 4.6 10	11 cg20494738 0.14 1.1 10	35
cg01881428 0.10 8.1 10	11 cg20978380 	0.10 5.6 10	10
cg16507569 0.10 1.1 10	10 cg25954028 	0.10 1.5 10	12
cg21893764 0.10 1.7 10	10 SERPINA3 cg06190732 0.11 1.2 10	12
cg00505762 0.10 3.8 10	10 SUPT3H cg01946401 	0.18 1.9 10	35
cg24311693 0.10 6.1 10	10 TGFB1 cg09926389 0.10 1.6 10	12
cg11835806 0.10 9.3 10	10 TP63 cg09085792 0.10 2.5 10	10
cg01194674 0.10 1.5 10	9
* Requirements for inclusion were P 0.01 and absolute methylation difference () 0.10. OA osteoarthritis (see Table 1 for other definitions).
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able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.38762/abstract).
We identified 20 CpG sites that met criteria for signifi-
cance (Table 3) (correlations for the 4 most highly
Figure 3. Pathways containing differentially methylated genes. A, Pathway centered upon SMAD3. B, Pathway centered upon Akt. Genes in yellow
are hypomethylated. Genes in blue are hypermethylated. C, Pathway enriched in genes with differentially methylated CpG sites highly correlated
with the histopathologic Mankin score. Genes in blue are those whose methylation correlated positively with the Mankin score. Genes in yellow are
those whose methylation correlated negatively with the Mankin score. Color figure can be viewed in the online issue, which is available at
http://onlinelibrary.wiley.com/doi/10.1002/art.38762/abstract.
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correlated of these CpG sites are shown in Supple-
mentary Figure 3, available on the Arthritis & Rheuma-
tology web site at http://onlinelibrary.wiley.com/doi/
10.1002/art.38762/abstract). Among these, 17 were nega-
tively correlated and 3 were positively correlated with
histologic grade. IPA revealed a single network linking
16 of the 17 associated genes, with hubs including
OA-associated NFB, MapK, TNF, and Pkc (Figure 3C).
DISCUSSION
We performed the first genome-wide DNA
methylation analysis of matched eroded and intact car-
tilage tissue from hips of 24 OA patients, offering a
unique insight into the progression of this disease. This
experimental design reflects a significant departure from
previous methylation studies, which have used control
tissue from disease-free cadaveric donors or patients
undergoing surgical procedures correcting femur neck
fractures, a population enriched in osteoporosis, a prac-
tice that may introduce its own set of confounding epi-
genetic aberrations. Our approach lessens the impact of
unknown confounders and reduces the contribution of
unknown genetic variation, but it does have inherent
limitations. In particular, our study design is unable to
detect methylation changes from early disease or differ-
ential methylation present throughout the affected joint,
as most of our intact cartilage samples had at least mini-
mal damage as evidenced by modified Mankin scores
0, which may explain the lack of concordance of our
findings with a previously reported knee OA genome-
wide methylation study that used disease-free controls.
Our experiments revealed several significant
findings. First, we found evidence for differential methyl-
ation among several genes that are intimately involved
in OA and among many with associated differential
expression, pointing toward a contribution of epigenetic
dysregulation to their pathogenic effects. Second, we
found moderate differential methylation among more
than one-third of known OA susceptibility genes, sug-
gesting DNA methylation as an alternate method for
disruption of their activity. Third, network analysis
identified pathways enriched in differentially methyl-
ated genes with hubs of known OA effectors, and
upstream regulator analysis was highly enriched in OA-
linked TGFB1 and ERG as well as in both known and
novel miRNAs. Finally, we described several CpG sites
whose methylation levels were highly correlated with the
histopathologic disease severity score, highlighting the
continuous nature of at least some epigenetic marks
during disease progression.
We identified 550 CpGs that met our criteria
for differential methylation (Table 1 and Figure 1)
(see Supplementary Table 7, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38762/abstract), associated with 312
unique genes, enriched in enhancers, previously hypoth-
esized as alternatives to promoters for epigenetic regu-
latory control (26). Only 3 of these genes were identified
Table 3. CpG sites most highly correlated with histopathologic modified Mankin score*
R2 
Illumina CpG
ID no. Correlation Gene symbol
UCSC location
group
UCSC island
group
0.91 0.36 cg14830791 	 – – –
0.90 0.34 cg06164260 	 BCL6 5-UTR, TSS 200 N-Shore
0.89 0.15 cg01918114 	 LMF1 Gene body –
0.88 0.45 cg11869862 
 – – N-Shelf
0.88 0.29 cg24601522 	 – – –
0.88 0.26 cg02331262 	 BANP 5-UTR, 5-UTR N-Shelf
0.87 0.30 cg01776691 	 CAMK2B Gene body S-Shore
0.87 0.42 cg08428188 	 – – Island
0.87 0.33 cg00242786 	 ADPRHL1 TSS 1,500 –
0.86 0.44 cg08189448 	 PAPPA TSS 200 N-Shore
0.86 0.25 cg10764440 	 FGF23 TSS 1,500 –
0.86 0.20 cg12491114 
 KRT19 TSS 1,500 S-Shore
0.86 0.17 cg05507566 
 CRIM1 Gene body –
0.85 0.39 cg18849583 	 AKAP6 5-UTR –
0.85 0.44 cg19009132 	 EMP1 5-UTR –
0.85 0.55 cg24075412 	 HRNBP3 TSS 1,500 –
0.85 0.22 cg00642679 	 RSBN1 TSS 1,500 S-Shore
0.85 0.23 cg04220482 	 GGH TSS 1,500 S-Shore
0.85 0.17 cg07461837 	 PYCARD TSS 1,500 S-Shore
0.85 0.29 cg09419900 	 PSTK TSS 200 N-Shore
* R2  linear coefficient of correlation (see Table 1 for other definitions).
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in a previous knee OA genome-wide methylation study
(RUNX1, MGAT1, and WIPF1) (19).
We observed novel differential methylation of
several genes involved in OA pathogenesis. Hypomethy-
lated FURIN processes a variety of ADAMTS molecules
involved in OA collagen degradation (27). Indeed, inhi-
bition of furin and other like enzymes is sufficient to sig-
nificantly reduce collagen breakdown and the levels of
active collagenase and MMP-2 in vitro (28). Furin is also
required to process TGF1 into its active form (29), and
inhibition of TGF1 in subchondral bone attenuates
OA (30).
The relationship between RUNX1 and OA is
unclear. A previous kneeOAgenome-wideDNAmethyl-
ation study identified RUNX1 as the most hypomethy-
lated CpG site in its assay (19). Despite its epigenetic
status, several studies have demonstrated, counterin-
tuitively, that RUNX-1 is underexpressed in OA chon-
drocytes (31,32), which we confirmed in our RT-PCR
analysis. Further study to characterize other epigenetic
modifications of the local chromatin environment (e.g.,
histone methylation/acetylation) is needed to explore
these seemingly contradictory findings. Our analysis
also identified hypomethylation of RUNX2, which is
known to be overexpressed in OA chondrocytes. RUNX-2
cooperates with CCAAT/enhancer binding protein  to
drive MMP-13, a major contributor to cartilage degra-
dation (33,34). Further, it is directly downstream of the
MEK/ERK pathway (35,36) and immediately upstream
of the MMP ADAMTS-5, both of which have well-
established roles in OA (37). This hypomethylation cor-
roborates previously observed overexpression of RUNX-2
in OA chondrocytes (34), although we did not find this
among our samples.
We also identified hypomethylation of DLX5,
which induces the expression of RUNX-2 in animal
models (23). We found both hypomethylation and over-
expression of HTRA1, which is elevated in synovial fluid
and cartilage explants from OA patients (38,39) where it
functions to degrade multiple components of the artic-
ular cartilage matrix (38,40), releasing MMPs. These
findings strongly suggest an epigenetic role in its patho-
logic expression. NFATC1, a key suppressor of OA, was
hypermethylated. This is consistent with previous studies
showing reduced NFATC1 expression in OA cartilage
(41), although we did not find a significant change in
expression among our samples.
Among structural genes, we found evidence for
hypermethylation and reduced expression of the type XI
collagen gene COL11A2. Mutations within COL11A2
have been associated with a number of hereditary osteo-
chondrodysplasias, featuring severe, early-onset OA de-
generative joint disease (42). Interestingly, polymor-
phisms within COL11A2 have been associated with
spinal degenerative disease, but not with OA of the hip
or knee (43). Our results suggest epigenetically medi-
ated silencing with effects similar to those caused by
genetic mutation. Hypermethylated FGFR2 is also im-
plicated in several genetic craniosynostosis syndromes
and is significantly up-regulated during chondrocyte
differentiation (44). In addition, we found significant
reduction in FGFR2 expression. These both suggest
examples of epigenetically mediated gene alterations
mimicking the phenotype of genetic mutations.
Upon initial review, among 64 genetic suscepti-
bility loci validated in 3 recent meta-analyses (7–9), only
3 associated genes (CLIP, COL11A2, and SUPT3H) met
criteria for differential methylation. This was likely due
to our strict 15% absolute methylation difference re-
quirement, as relaxing this to 10% revealed a remark-
able 83 differentially methylated CpG sites among 24
known OA susceptibility genes. This is striking; by this
definition, 38% of the known OA susceptibility genes
are associated with at least moderate differential DNA
methylation (Table 2). Much like findings for COL11A2
and FGFR2, this suggests that gene disruption leading to
disease phenotype may be accomplished either by ge-
netic mutation or epigenetic dysregulation.
IPA revealed that many differentially methylated
genes are present in networks known to be involved in
OA. The first network identified centered on SMAD3
(itself hypomethylated in our assay), which functions in
a highly correlated manner with TGF to maintain
articular cartilage (45) (Figure 3A). A second network
included the aforementioned NFATC1, HTRA1, and
DLX5. Akt was central in this network, which up-
regulates MMP production through hypoxia-inducible
factor 2 and NF-B and contributes to OA pathology
(Figure 3B) (46). Both of these networks demonstrate
likely indirect effects of differentially methylated genes
on known OA effector pathways.
Several IPAs identified upstream regulators as
enriched among differentially methylated genes (see
Supplementary Table 5, available on the Arthritis &
Rheumatology web site at http://onlinelibrary.wiley.com/
doi/10.1002/art.38762/abstract). Of the 5 top miRNAs, 2
have previously reported associations with OA. These
are miR-9, overexpressed 8-fold in OA cartilage (47),
and miR-27a, linked to MMP-13 and insulin-like growth
factor binding protein 5 in vitro (48). The other miRNAs
we found enriched among differentially methylated
genes are novel associations, and these deserve further
study. The most highly enriched non-miRNA upstream
regulator we identified was the Ets-related gene ERG,
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which plays a crucial role in cartilage development
through chondrocyte growth and hypertrophy regulation
(49). Also highly enriched was TGFB1, present in 11%
(n 44) of differentially methylated genes mapped, with
a P value of 4.4  10	5. Zhen et al recently described
chondroprotection in an anterior cruciate ligament de-
stabilization mouse model of OA via both TGF recep-
tor knockout and anti-TGF antibody treatment of
subchondral bone, which was linked to a reduction in
mesenchymal stem cell recruitment to the site of injury
(30). These observed effects might be influenced by
epigenetic dysregulation of TGF-targeted genes.
Finally, we identified several CpG sites whose
methylation status was highly correlated with the histo-
logic grade of OA (Table 3) (see Supplementary Figure
3, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.38762/
abstract). All of these genes, with the exception of
FGF23, represent novel associations with OA. Interest-
ingly, none met our criteria for significant differential
methylation in the larger categorical experiment. IPA
identified a single associated network that contained
15 of the 17 differentially methylated genes; the key
hubs of this network are known OA- and inflammation-
associated proteins and transcription factors including
Mapk, TNF, and Pkc (Figure 3C). This finding of a
strong association of methylation with histologic grade
gives hope for the future identification of biomarkers of
disease activity and provides evidence that epigenetic
contributions to OA pathology may exist along a contin-
uum, rather than being a binary phenomenon.
In summary, our present set of experiments con-
stituted the first genome-wide DNA methylation study
in hip OA using a unique method comparing eroded and
intact cartilage from the same joint. We demonstrated
a number of differentially methylated CpG sites, several
of these associated with OA-implicated genes, and we
offered the first description of differential methylation
among OA susceptibility genes. Furthermore, we iden-
tified a number of functional networks highly enriched
in differentially methylated genes with well-known OA
regulators as hubs. Finally, we offered a novel descrip-
tion of strong correlation between the methylation level
of several CpG sites and the histologic grade of OA
cartilage, and we found that these associated genes
cluster in a single network containing well-known OA
hubs. These findings offer further evidence that OA is a
complex disease involving complex genomic–epigenomic
interactions.
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